Asia Pacific Next Generation Sequencing Market

The Asia Pacific next-generation sequencing market is anticipated to reach USD 7.38 billion in 2030 from USD 3.40 billion in 2025, with a significant CAGR of 16.7%. Major growth drivers of the Asia Pacific next-generation sequencing market include substantial public and private investment in genomics, as well as national genome and precision medicine initiatives in China, Japan, India, South Korea, Singapore, and Australia. These initiatives are complemented by ongoing advances that are lowering sequencing costs and improving throughput and data analytics.

The Asia Pacific next-generation sequencing market is consolidated. Prominent players in the European next-generation sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Wuxi Biologics (China), Takara Bio (Japan), and MGI Tech Co., Ltd. (China), among others.

To know about the assumptions considered for the study download the pdf brochure

In July 2022, BGI Group (China) received CE-IVDD approval for the homologous recombination deficiency detection kit (Consumables), which detects genomic homologous recombination deficiency (HRD).

Illumina, Inc. is a key player in the Asia Pacific NGS market. It supports users across research, clinical diagnostics, and translational programs. Its regional offering includes sequencing systems, consumables, and informatics, including cloud-enabled analysis and workflow management tools. This offering is well-suited to Asia Pacific labs scaling routine sequencing and seeking faster, more standardized runs. In the Asia Pacific, Illumina platforms are widely utilized for oncology testing, rare disease genomics, reproductive health screening, and infectious disease surveillance. Demand is also rising from population genomics and extensive cohort studies underway across several Asia Pacific countries. Alongside products, Illumina supports customers with sequencing services and instrument servicing, plus training, workflow assessment, and application support to help labs adopt and expand NGS. The company continues to enhance accuracy, throughput, and automation readiness while helping labs align with country-specific validation and compliance requirements across the region.

Thermo Fisher Scientific Inc. is a prominent competitor in the Asia-Pacific NGS market. The company has established a strong presence in this region through a combination of direct operations and partnerships with channels, which in turn support academic institutions, national reference laboratories, hospitals, and biopharmaceutical clients. Its product portfolio is well-suited to the Asia Pacific market, especially in laboratories that require scalable throughput, fast turnaround time, and flexibility. In the Asia-Pacific region, Thermo Fisher Scientific’s next-generation sequencing solutions are led by the Ion Torrent platform, comprising product offerings such as Ion GeneStudio, along with related Ion AmpliSeq Panels. Additionally, Thermo Fisher Scientific is supported by an end-to-end solutions platform that covers sample preparation, reagents, automation solutions, and application bioinformatics, which assists laboratories in standardizing their processes and improving hands-on time.

Wuxi Biologics (China) is a significant enabler of the Asia Pacific NGS market, despite not being an NGS instrument vendor. Across the Asia Pacific, many biopharma and biotech teams rely on partners such as WuXi to generate sequencing-backed evidence during biologic development and manufacturing. This includes sequencing-supported characterization work that helps teams accelerate from early development into clinical and commercial stages. In the Asia Pacific, WuXi Biologics supports NGS-driven needs in areas such as cell line and clone characterization, genetic stability checks, and process- and product-related impurity investigations, where deeper genomic insight is increasingly expected. It also helps sponsors when they need scalable analytics, documentation readiness, and consistent data packages across multi-site programs. As Asia Pacific pipelines grow in mAbs, bispecifics, and next-generation biologics, demand for sequencing-based assays and interpretation continues to rise. This positions WuXi Biologics as a practical route for customers to adopt NGS workflows without having to build every capability in-house.

Market Ranking

The Asia Pacific next-generation sequencing market is a fast-paced and highly competitive one. It comprises global and regional leaders, as well as a large number of local service providers. Market dynamics are driven by price sensitivity, rapid capacity expansion, and varying adoption across countries. The Asia Pacific market primarily comprises China, Japan, South Korea, Australia, and India, which have extensive healthcare infrastructure and strong national genomics initiatives. Illumina leads in Asia Pacific with a broad portfolio of platform offerings and a strong ecosystem of consumables, library prep, and informatics solutions. Their systems are widely used in research, population genomics, and translational research, including applications in oncology and the study of rare diseases. Thermo Fisher Scientific is another key competitor in the market, particularly through its Ion Torrent platform solutions, which are widely used for targeted sequencing, with a focus on panel-based translational research and diagnostics. Overall, this market is highly fragmented, with a large number of sequencing providers, laboratories offering end-to-end solutions, and informatics companies providing analytical tools. Significant trends in the Asia Pacific region include higher demand for end-to-end solutions, increased laboratory automation, and a growing need for cloud-enabled analysis, with governance policies supporting this mode of study.

Related Reports:

Asia Pacific Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com